BioNTech to support trial access for cancer immunotherapies
BioNTech SE and the UK government have jointly agreed to provide up to 10,000 patients with personalised cancer immunotherapies by 2030. Signing of this agreement builds on a memorandum of...
United Kingdom United States Europe America Asia Ratingsanalyst Consensussellbuymean Deutsch Deutschland Nederlands Nederland
Source: marketscreener.com